Viral genome changes and the impact of viral genome persistence
in myocardium of patients with inflammatory cardiomyopathy

J 2018

Viral genome changes and the impact of viral genome persistence in myocardium of patients with inflammatory cardiomyopathy

MLEJNEK, Dalibor; Jan KREJČÍ; Petr HUDE; Eva OZÁBALOVÁ; Víta ŽAMPACHOVÁ et al.

Základní údaje

Originální název

Viral genome changes and the impact of viral genome persistence in myocardium of patients with inflammatory cardiomyopathy

Autoři

MLEJNEK, Dalibor; Jan KREJČÍ; Petr HUDE; Eva OZÁBALOVÁ; Víta ŽAMPACHOVÁ; Radka STEPANOVA; Iva SVOBODOVÁ; Tomáš FREIBERGER ; Eva NEMCOVA a Lenka ŠPINAROVÁ

Vydání

Archives of Medical Science, Poland, Termedia Publishing House, 2018, 1734-1922

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Polsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.380

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/18:00104916

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

polymerase chain reaction; myocarditis; dilated cardiomyopathy; endomyocardial biopsy; inflammatory cardiomyopathy

Štítky

14110112, 14110115, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 2. 2019 15:56, Soňa Böhmová

Anotace

V originále

Introduction: Viral infections are considered the most frequent cause of myocarditis and dilated cardiomyopathy (DCM). Material and methods: We investigated the changes in viral presence and the impact of viral genome persistence in the myocardium on echocardio-graphic parameters, functional status and some laboratory parameters in a 6-month follow-up. Fifty-four patients with recent onset DCM, left ventricular ejection fraction < 40% and biopsy-proven myocarditis (> 14 mononuclear leukocytes/mm(2) and/or > 7 T-lymphocytes/mm(2)) were enrolled. Polymerase chain reaction (PCR) was performed to detect pathogens in the myocardium. Patients were divided according to the administered therapy: standard heart failure medication (46 patients) and immunosuppressive therapy (8 patients). Results: In the standard heart failure medication group viral clearance was observed in 13 patients and viral persistence in 24 patients in the follow-up period. Comparing both groups, there was no statistically significant difference - LVEF improvement of 12.0 +/- 11.4% vs. 18.3 +/- 12.6%, decrease in NYHA class of 0.7 +/- 0.7 vs. 1.0 +/- 0.7, decline in NT-proBNP of 1335 +/- 1933 ng/I vs. 1942 +/- 3242 ng/I and decrease in infiltrating leukocytes of 11.1 +/- 15.8 vs. 6.7 +/- 23.0 cells/mm(2) and T-lymphocytes of 5.8 +/- 15.1 vs. 1.8 +/- 10.9 cells/mm(2) (all p = NS). A decrease in PCR positive patients from 37 to 29 was observed. The number of PVB19 positive PCR findings decreased from 5 to 4 in patients with immunosuppressive therapy. Conclusions: A decrease in the number of positive PCR findings in control endomyocardial biopsy was observed. Viral genome persistence was not associated with worse outcome in short-term follow-up.

Návaznosti

MUNI/A/1443/2014, interní kód MU

Název: Vývoj virové nálože v myokardu u nemocných po srdeční transplantaci a se zánětlivou kardiomyopatií.

Investor: Masarykova univerzita, Vývoj virové nálože v myokardu u nemocných po srdeční transplantaci a se zánětlivou kardiomyopatií., DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

MLEJNEK, Dalibor; Jan KREJČÍ; Petr HUDE; Eva OZÁBALOVÁ; Víta ŽAMPACHOVÁ; Radka STEPANOVA; Iva SVOBODOVÁ; Tomáš FREIBERGER; Eva NEMCOVA a Lenka ŠPINAROVÁ. Viral genome changes and the impact of viral genome persistence in myocardium of patients with inflammatory cardiomyopathy. Archives of Medical Science. Poland: Termedia Publishing House, 2018, roč. 14, č. 6, s. 1245-1253. ISSN 1734-1922. Dostupné z: https://doi.org/10.5114/aoms.2018.79002.

@article{1478077,
   author = {Mlejnek, Dalibor and Krejčí, Jan and Hude, Petr and Ozábalová, Eva and Žampachová, Víta and Stepanova, Radka and Svobodová, Iva and Freiberger, Tomáš and Nemcova, Eva and Špinarová, Lenka},
   article_location = {Poland},
   article_number = {6},
   doi = {https://doi.org/10.5114/aoms.2018.79002},
   keywords = {polymerase chain reaction; myocarditis; dilated cardiomyopathy; endomyocardial biopsy; inflammatory cardiomyopathy},
   language = {eng},
   issn = {1734-1922},
   journal = {Archives of Medical Science},
   title = {Viral genome changes and the impact of viral genome persistence in myocardium of patients with inflammatory cardiomyopathy},
   volume = {14},
   year = {2018}
}

TY  - JOUR
ID  - 1478077
AU  - Mlejnek, Dalibor - Krejčí, Jan - Hude, Petr - Ozábalová, Eva - Žampachová, Víta - Stepanova, Radka - Svobodová, Iva - Freiberger, Tomáš - Nemcova, Eva - Špinarová, Lenka
PY  - 2018
TI  - Viral genome changes and the impact of viral genome persistence in myocardium of patients with inflammatory cardiomyopathy
JF  - Archives of Medical Science
VL  - 14
IS  - 6
SP  - 1245-1253
EP  - 1245-1253
PB  - Termedia Publishing House
SN  - 17341922
KW  - polymerase chain reaction
KW  - myocarditis
KW  - dilated cardiomyopathy
KW  - endomyocardial biopsy
KW  - inflammatory cardiomyopathy
N2  - Introduction: Viral infections are considered the most frequent cause of myocarditis and dilated cardiomyopathy (DCM). Material and methods: We investigated the changes in viral presence and the impact of viral genome persistence in the myocardium on echocardio-graphic parameters, functional status and some laboratory parameters in a 6-month follow-up. Fifty-four patients with recent onset DCM, left ventricular ejection fraction < 40% and biopsy-proven myocarditis (> 14 mononuclear leukocytes/mm(2) and/or > 7 T-lymphocytes/mm(2)) were enrolled. Polymerase chain reaction (PCR) was performed to detect pathogens in the myocardium. Patients were divided according to the administered therapy: standard heart failure medication (46 patients) and immunosuppressive therapy (8 patients). Results: In the standard heart failure medication group viral clearance was observed in 13 patients and viral persistence in 24 patients in the follow-up period. Comparing both groups, there was no statistically significant difference - LVEF improvement of 12.0 +/- 11.4% vs. 18.3 +/- 12.6%, decrease in NYHA class of 0.7 +/- 0.7 vs. 1.0 +/- 0.7, decline in NT-proBNP of 1335 +/- 1933 ng/I vs. 1942 +/- 3242 ng/I and decrease in infiltrating leukocytes of 11.1 +/- 15.8 vs. 6.7 +/- 23.0 cells/mm(2) and T-lymphocytes of 5.8 +/- 15.1 vs. 1.8 +/- 10.9 cells/mm(2) (all p = NS). A decrease in PCR positive patients from 37 to 29 was observed. The number of PVB19 positive PCR findings decreased from 5 to 4 in patients with immunosuppressive therapy. Conclusions: A decrease in the number of positive PCR findings in control endomyocardial biopsy was observed. Viral genome persistence was not associated with worse outcome in short-term follow-up.
ER  -

MLEJNEK, Dalibor; Jan KREJČÍ; Petr HUDE; Eva OZÁBALOVÁ; Víta ŽAMPACHOVÁ; Radka STEPANOVA; Iva SVOBODOVÁ; Tomáš FREIBERGER; Eva NEMCOVA a Lenka ŠPINAROVÁ. Viral genome changes and the impact of viral genome persistence in myocardium of patients with inflammatory cardiomyopathy. \textit{Archives of Medical Science}. Poland: Termedia Publishing House, 2018, roč.~14, č.~6, s.~1245-1253. ISSN~1734-1922. Dostupné z: https://doi.org/10.5114/aoms.2018.79002.

Přehled o publikaci